Pharmacologic Management of Alzheimer Disease Part II: Antioxidants,Antihypertensives,and Ergoloid Derivatives

Abstract

Spanish

French

OBJECTIVE:

To provide information about research evaluating antioxidants in Alzheimer disease (AD) and to discuss the potential role of β-blockers, angiotensin-converting enzyme inhibitors, clonidine, guanfacine, nimodipine, and ergoloid derivatives in AD therapy.

DATA SOURCES:

Studies, review articles, and editorials identified from MEDLINE searches (from 1989 to 1997) and bibliographies of identified articles.

STUDY SELECTION:

Studies and review articles addressing antioxidant, antihypertensive, and ergoloid derivative pharmacotherapy research.

DATA EXTRACTION:

Pertinent information was selected and the data synthesized into a review format.

DATA SYNTHESIS:

AD is a progressive neuropsychiatric disorder of unknown etiology. Studies evaluating the possible association between a free radical mechanism in AD and the potential role of antioxidants are reviewed. Additionally, the role of β-blockers, angiotensin-converting enzyme inhibitors, clonidine, guanfacine, nimodipine, and ergoloid derivatives in AD management are discussed.

CONCLUSIONS:

Preliminary evidence suggests that antioxidants may have a protective effect against the development of AD. Additional prospective, double-blind, placebo-controlled studies are needed to determine the role of antioxidants in the prevention and management of AD. Understanding the role of antioxidants in AD may suggest alternative agents that have similar pharmacologic activity. β-Blockers may be an option to control agitation in AD patients for whom anxiolytics or antipsychotics are ineffective or are contraindicated because of their adverse effect profiles. Other agents that may have a role in AD therapy include angiotensin-converting enzyme inhibitors, nimodipine, and ergoloid derivatives. Clonidine and guanfacine have thus far shown little promise in improving cognitive function in AD. Further prospective, double-blind, placebo-controlled trials will be necessary to elucidate the role of these agents in AD management.

Keywords

antioxidants antihypertensives ergoloid derivatives Alzheimer disease

Get full access to this article

View all access options for this article.

References

Katzman

Kawas

. The epidemiology of dementia and Alzheimer disease. In: Terry

Katzman

Bick

, eds. Alzheimer disease. New York: Raven Press, 1994: 105–22.

Frölich

Riederer

. Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung 1995;45: 443–6.

Lohr

. Oxygen radicals and neuropsychiatric illness: Some speculations. Arch Gen Psychiatry 1991;48: 1097–106.

Lohr

Browning

. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995;31: 159–65.

Ehmann

Markesbery

Alauddin

Hossain

TIM

Brubaker

. Brain trace elements in Alzheimer's disease. Neurotoxicology 1986;7: 197–206.

Thompson

Markesbery

Ehmann

Mao

Y-X

Vance

. Regional brain trace-element studies in Alzheimer's disease. Neurotoxicology 1988;9: 1–8.

Samudralwar

DiPrete

Markesbery

Ehmann

. Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 1995;130: 139–45.

Good

Perl

Bierer

Schmeidler

. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: A laser microprobe (LAMMA) study. Ann Neurol 1992;31: 286–92.

Coyle

Puttfarcken

. Oxidative stress, glutamate and neurodegenerative disorders. Science 1993;262: 689–95.

10.

Lovell

Ehmann

Butler

Markesbery

. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995:45: 1594–601.

11.

Lockhart

Benicourt

Junien

Privat

. Inhibitors of free radical formation fail to attenuate direct P-amyloid₂₅-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res 1994;39: 494–505.

12.

Reynolds

Cutts

. Free radical damage in Down's syndrome brain (abstract). Biochem Soc Trans 1993;21:221S.

13.

Tesco

Latorraca

Piersanti

Sorbi

. Free radical injury in skin cultured fibroblasts from Alzheimer's disease patients. Ann N Y Acad Sci 1992;673: 149–53.

14.

Jackson

Holland

Williams

Dickerson

. Vitamin E and Alzheimer's disease in subjects with Down's syndrome. J Ment Defic Res 1988;32: 479–84.

15.

Metcalfe

Bowen

Muller

DPR

. Vitamin E concentrations in human brain of patients with Alzheimer's disease, fetuses with Down's syndrome, centenarians and controls. Neurochem Res 1989;14: 1209–12.

16.

Adams

Jr Klaidman

Odunze

Shen

Miller

. Alzheimer's and Parkinson's disease brain levels of glutathione, glutathione disulfide and vitamin E. Mol Chem Neuropathol 1991;14: 213–26.

17.

Goodman

Mattson

. Secreted forms of beta-amyloid precursor protein protect hippocampal neurons against amyloid beta-peptide-induced oxidative injury. Exp Neurol 1994;128: 1–12.

18.

Dyrks

Hartmann

Masters

Beyreuther

. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 1992;267: 18210–7.

19.

Behl

Davis

Cole

Schubert

. Vitamin E protects nerve cells from amyloid-P protein toxicity. Biochem Biophys Res Commun 1992;186: 944–50.

20.

McKhann

Drachman

Folstein

Katzman

Price

Stadlan

. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force of Alzheimer's Disease. Neurology 1984;34: 939–44.

21.

de la Torre

Casado

López-Fernández

Carrascosa

Casado

Venarucci

Human aging brain disorders: Role of antioxidant enzymes. Neurochemical Res 1996;21:885–8.

22.

Richardson

Subbarao

Ang

. On the possible role of iron-induced free radical peroxidation in neural degeneration in Alzheimer's disease. Ann N Y Acad Sci 1992;648: 326–7.

23.

Evans

Morris

. Is a randomized trial of antioxidants in the primary prevention of Alzheimer disease warranted? Alzheimer Dis Assoc Disord 1996;10 (suppl 1): 45–9.

24.

Thal

. Potential prevention strategies for Alzheimer disease. Alzheimer Dis Assoc Disord 1996;10 (suppl 1): 6–8.

25.

Bolkenius

Verne-Mismer

Wagner

Grisar

. Amphiphilic α-tocopherol analogues as inhibitors of brain lipid peroxidation. Eur J Pharmacol 1996;298: 37–43.

26.

Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176–83.

27.

Fahn

. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;32 (suppl):S128–32.

28.

Sano

Ernesto

Thomas

Melville

Schafer

Grundman

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216–22.

29.

Morris

. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43: 2412–4.

30.

Folstein

McHugh

. “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189–98.

31.

Rosen

Mohs

Davis

. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141: 1356–64.

32.

Blessed

Tomlinson

Roth

. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114: 797–811.

33.

Drachman

Leber

. Treatment of Alzheimer's disease — Searching for a breakthrough, settling for less (editorial). N Engl J Med 1997;336: 1245–7.

34.

Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330: 1029–35.

35.

Socci

Crandall

Arendash

. Chronic antioxidant treatment improves the cognitive performance of aged rats. Brain Res 1995;693: 88–94.

36.

Sack

Socci

Crandall

Arendash

. Antioxidant treatment with phenyl-α-tert-butyl nitrone (PBN) improves the cognitive performance and survival of aging rats. Neurosci Lett 1996;205: 181–4.

37.

Musleh

Bruce

Malfroy

Baudry

. Effects of EUK-8, a synthetic catalytic superoxide scavenger, on hypoxia- and acidosis-induced damage in hippocampal slices. Neuropharmacology 1994;33: 929–34.

38.

Bruce

Malfroy

Baudry

. β-amyloid toxicity in organotypic hippocampal cultures: Protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci U SA 1996;93: 2312–6.

39.

Shimohama

Taniguchi

Fujiwara

Kameyama

. Changes in β-adrenergic receptor subtypes in Alzheimer-type dementia. J Neurochem 1987;48: 1215–21.

40.

Kalaria

Andorn

Tabaton

Whitehouse

Harik

Unnerstall

. Adrenergic receptors in aging and Alzheimer's disease: Increased β-receptors in prefrontal cortex and hippocampus. J Neurochem 1989;53: 1772–81.

41.

Lemmer

Langer

Ohm

Bohl

. Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease. Naunyn Schmiedebergs Arch Pharmacol 1993;347: 214–9.

42.

Weiler

Mungas

Bernick

. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988;1: 226–30.

43.

Greendyke

Kanter

. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: A double blind study. J Clin Psychiatry 1986;47: 423–6.

44.

Greendyke

Kanter

Schuster

Verstreate

Wootton

. Propranolol treatment of assaultive patients with organic brain disease: Double blind crossover placebo-controlled study. J Nerv Ment Dis 1986;174: 290–4.

45.

Greendyke

Schuster

Wooton

. Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol 1984;4:5.

46.

Shankle

Nielson

Coman

. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995;9: 233–7.

47.

Chui

Victoroff

Margolin

Jagust

Shankle

Katzman

. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992;42: 473–80.

48.

Cohen-Mansfield

. Cohen-Mansfield agitation inventory. Rockville, MD: Research Institute of the Hebrew Home of Greater Washington, 1991.

49.

Dumon

Catteau

Lanvin

Dupuis

. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992;149: 647–50.

50.

Adler

Peselow

Rosenthal

Angrist

. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: An interim analysis. Psychopharmacol Bull 1993;29: 283–6.

51.

Sachdev

Loneragan

. Intravenous benztropine and propranolol challenges in tardive akathisia. Psychopharmacology 1993;113: 119–22.

52.

Koller

. Long-acting propranolol in essential tremor. Neurology 1985;35: 108–10.

53.

Koller

. Dose—response relationship of propranolol in the treatment of essential tremor. Arch Neurol 1986;43: 42–3.

54.

Koller

Vetere-Overfield

. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989;39: 1587–8.

55.

Koller

Krause

Hoffmeister

Ganten

. Endogenous brain angiotensin II disrupts passive avoidance behavior in rats. Neurosci Lett 1979;14: 71–5.

56.

Costall

Coughlan

Horovitz

Kelly

Naylor

Tomkins

. The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognition. Pharmacol Biochem Behav 1989;33: 573–9.

57.

Croog

Levine

Testa

Brown

Bulpitt

Jenkins

The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657–64.

58.

Sudilovsky

Cutler

Sramek

Wardle

Veroff

Mickelson

A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:105–11.

59.

Task Force on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980.

60.

Reisberg

Ferris

De Leon

Crook

. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139: 1136–9.

61.

Veroff

Cutler

Sramek

Prior

Mickelson

Hartman

. A new assessment tool for neuropsychopharmacologic research: The Computerized Neuropsychological Test Battery. J Geriatr Psychiatry Neurol 1991;4: 211–7.

62.

Bondareff

Mountjoy

Roth

. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982;32: 164–8.

63.

Chan-Palay

Asan

. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989;287: 373–92.

64.

Arnsten

Goldman-Rakic

. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985;230: 1273–6.

65.

Arnsten

Cai

Goldman-Rakic

. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci 1988;8: 4287–98.

66.

Mohr

Schlegel

Fabbrini

Williams

Mouradian

Mann

Clonidine treatment of Alzheimer's disease. Arch Neurol 1989;46:376–8.

67.

Bierer

Aisen

Davidson

Ryan

Schmeidler

Davis

. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia 1994;5: 243–6.

68.

Schlegel

Mohr

Williams

Mann

Gearing

Chase

. Guanfacine treatment of Alzheimer's disease. Clin Neuropharmacol 1989;12: 124–8.

69.

Mattis

. Mental status examination for organic mental syndrome in the elderly. In: Bellack

Karasu

, eds. Geriatric psychiatry. New York: Grune & Stratton, 1976: 77–121.

70.

Crook

Wilner

Rothwell

Winterling

McEntee

. Noradrenergic intervention in Alzheimer's disease. Psychopharmacol Bull 1992;28: 67–70.

71.

Benton

. Revised visual retention test. 4th ed. New York: The Psychological Corporation, 1974.

72.

Wechsler

. Wechsler memory scale — Revised manual. San Antonio, TX: The Psychological Corporation, 1987.

73.

Miller

Mahoney

Jann

. Therapeutic frontiers in Alzheimer's disease. Pharmacotherapy 1992;12: 217–31.

74.

Schmage

Bergener

. Global rating, symptoms, behaviors, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int Psychogeriatr 1992;4 (suppl 1): 89–99.

75.

Ban

Morey

Aguglia

Azzarelli

Balsano

Marigliano

Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:525–51.

76.

Parnetti

Senin

Carosi

Baasch

. Mental deterioration in old age: Results of two multicenter, clinical trials with nimodipine. Clin Ther 1993;15: 394–406.

77.

Tollefson

. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27: 1133–42.

78.

Buschke

. Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 1973;12: 543–50.

79.

Fischhof

. Divergent neuroprotective effects of nimodipine in PDD and MID provide indirect evidence of disturbances in Ca+2 homeostasis in dementia. Methods Find Exp Clin Pharmacol 1993;15: 549–55.

80.

Hachinski

Iliff

Zilhka

Du-Boulay

McAllister

Marshall

Cerebral blow flow in dementia. Arch Neurol 1975;32:632–7.

81.

Shader

Harmatz

Salzman

. A new scale for assessment in geriatric populations: Sandoz clinical assessment-geriatric (SCAG). J Am Geriatr Soc 1974;22: 107–13.

82.

Erzigkeit

. Der syndrom-kurtest zur erfassung von aufmerksamkeits und gedächtnisstörungen. 2nd ed. Vless, Germany: Vaterstetten, 1986.

83.

Wadworth

Chrisp

. Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging 1992;2: 153–73.

84.

Schnieder

Olin

. Overview of clinical trials of Hydergine in dementia. Arch Neurol 1994;51: 787–98.

85.

Saletu

Paulus

Linzmayer

Anderer

Semlitsch

Griinberger

Nicergoline in senile dementia of Alzheimer type and multi-in-farct dementia: A double-blind, placebo-controlled, clinical and EEG/ ERP mapping study. Psychopharmacology 1995;117:385–95.

86.

Work Group to Revise DSM-III. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987.